{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:45:56Z","timestamp":1793108756878,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jpsychires.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T23:33:37Z","timestamp":1544398417000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Does the frequency of administration of long acting injectable antipsychotics impact psychiatric outcomes and adverse effects: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"109","author":[{"given":"Erich","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebnem","family":"Kamalvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpsychires.2018.12.004_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.jpsychires.2018.12.004_bib2","doi-asserted-by":"crossref","first-page":"A713","DOI":"10.1016\/j.jval.2017.08.1890","article-title":"Cost-effectiveness analysis of the paliperidone palmitate 3-month formulation versus 1-month formulation from a healthcare payer perspective","volume":"20","author":"Arikan","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jpsychires.2018.12.004_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-14-7","article-title":"A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection","volume":"14","author":"Atkins","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2018.12.004_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eurpsy.2011.02.005","article-title":"Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade","volume":"27","author":"Barkhof","year":"2012","journal-title":"Eur. Psychiatry: J. Asso. Eur. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2018.12.004_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst. Rev."},{"issue":"3","key":"10.1016\/j.jpsychires.2018.12.004_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1176\/ajp.139.3.312","article-title":"Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect","volume":"139","author":"Chouinard","year":"1982","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2018.12.004_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1472-6963-11-236","article-title":"The cost associated with administering risperidone long-acting injections in the Australian community","volume":"11","author":"Dalton","year":"2011","journal-title":"BMC Health Serv. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2018.12.004_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.jpsychires.2018.12.004_bib9","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1185\/03007995.2015.1085849","article-title":"Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia","volume":"31","author":"Gopal","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"issue":"04","key":"10.1016\/j.jpsychires.2018.12.004_bib10","first-page":"688","article-title":"Efficacy and safety of paliperidone palmitate or long-acting injectable risperidone in patients with schizophrenia","volume":"17","author":"Guo","year":"2017","journal-title":"Prog. Mod. Biomed."},{"key":"10.1016\/j.jpsychires.2018.12.004_bib11","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jpsychires.2018.12.004_bib12","first-page":"530","article-title":"An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate","volume":"54","author":"Kern Sliwa","year":"2018","journal-title":"Psychiatr. Care"},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2018.12.004_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.schres.2015.04.028","article-title":"A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome","volume":"166","author":"Kisely","year":"2015","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.jpsychires.2018.12.004_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v69n0512","article-title":"An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia","volume":"69","author":"Lauriello","year":"2008","journal-title":"J. Clin. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2018.12.004_bib15","article-title":"Systematic review, meta-analysis and meta-regression of predictors of placebo response in acute schizophrenia","volume":"44","author":"Leucht","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.jpsychires.2018.12.004_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.jpsychires.2018.12.004_bib17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.euroneuro.2012.11.004","article-title":"Equipercentile linking of the BPRS and the PANSS","volume":"23","author":"Leucht","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2018.12.004_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2018.12.004_bib19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3111\/13696998.2012.681531","article-title":"Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden","volume":"15","author":"Mehnert","year":"2012","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.jpsychires.2018.12.004_bib20","first-page":"167","article-title":"Association of multidrug resistance 1 gene polymorphism with the clinical efficacy of paliperidone and risperidone in schizophrenic patients","volume":"43","author":"Mi","year":"2010","journal-title":"Chin. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2018.12.004_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2018.12.004_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2018.12.004_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.64719\/pb.4369","article-title":"A phase-1 study comparing pharmacokinetic and safety profiles of three different dose intervals of aripiprazole lauroxil","volume":"47","author":"Risinger","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jpsychires.2018.12.004_bib24","article-title":"Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study","volume":"13","author":"Savitz","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"7","key":"10.1016\/j.jpsychires.2018.12.004_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.jpsychires.2018.12.004_bib26","first-page":"1072","article-title":"Comparison of efficacy of paliperidone palmitate and risperidone for depot suspension in the treatment of schizophrenia","volume":"35","author":"Song","year":"2016","journal-title":"Herald Med."},{"issue":"6","key":"10.1016\/j.jpsychires.2018.12.004_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.jpsychires.2018.12.004_bib28","first-page":"1124","article-title":"Clinical effect of paliperidone palmitate and risperdal consta in the treatment of patients with schizophrenia","volume":"31","author":"Wang","year":"2015","journal-title":"Chin. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2018.12.004_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1185\/03007995.2012.657300","article-title":"Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia","volume":"28","author":"Witte","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.jpsychires.2018.12.004_bib30","first-page":"2066","article-title":"Clinical efficacy of two long-acting antipsychotics in the treatment of patients with schizophrenia","volume":"33","author":"Yin","year":"2016","journal-title":"J. Clin. Res."},{"issue":"5","key":"10.1016\/j.jpsychires.2018.12.004_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40258-013-0050-0","article-title":"Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany","volume":"11","author":"Zeidler","year":"2013","journal-title":"Appl. Health Econ. Health Policy"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618310495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618310495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:45:13Z","timestamp":1775299513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395618310495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":31,"alternative-id":["S0022395618310495"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2018.12.004","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the frequency of administration of long acting injectable antipsychotics impact psychiatric outcomes and adverse effects: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}